CVS Health Corporation (NYSE:CVS)‘s stock had its “hold” rating reiterated by research analysts at Robert W. Baird in a research note issued to investors on Friday, October 27th. They currently have a $77.00 price target on the pharmacy operator’s stock. Robert W. Baird’s price objective would suggest a potential upside of 8.47% from the company’s previous close.
Other equities analysts have also recently issued reports about the company. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and issued a $95.00 target price on shares of CVS Health Corporation in a report on Monday, October 9th. Guggenheim reaffirmed a “buy” rating on shares of CVS Health Corporation in a report on Monday, July 3rd. SunTrust Banks, Inc. set a $85.00 price target on CVS Health Corporation and gave the company a “buy” rating in a report on Thursday, October 12th. Mizuho set a $90.00 price target on CVS Health Corporation and gave the company a “buy” rating in a report on Tuesday, October 24th. Finally, Jefferies Group LLC reissued a “hold” rating and set a $82.00 price target on shares of CVS Health Corporation in a report on Friday, July 14th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and fourteen have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $85.82.
CVS Health Corporation (NYSE:CVS) opened at $70.99 on Friday. The firm has a market capitalization of $71,912.30, a price-to-earnings ratio of 12.43, a PEG ratio of 1.22 and a beta of 0.86. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.55 and a current ratio of 1.05. CVS Health Corporation has a twelve month low of $66.45 and a twelve month high of $84.72.
CVS Health Corporation (NYSE:CVS) last released its quarterly earnings results on Monday, November 6th. The pharmacy operator reported $1.50 earnings per share for the quarter, beating the consensus estimate of $1.49 by $0.01. CVS Health Corporation had a return on equity of 16.96% and a net margin of 2.77%. The firm had revenue of $46.18 billion for the quarter, compared to analysts’ expectations of $46.17 billion. During the same period in the prior year, the firm earned $1.64 EPS. The company’s revenue was up 3.5% compared to the same quarter last year. sell-side analysts predict that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “CVS Health Corporation (CVS) Earns Hold Rating from Robert W. Baird” was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this story on another site, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this story can be read at https://ledgergazette.com/2017/11/13/cvs-health-corporation-cvs-given-hold-rating-at-robert-w-baird.html.
In other news, Director Richard J. Swift sold 2,500 shares of the business’s stock in a transaction on Wednesday, August 16th. The shares were sold at an average price of $79.62, for a total transaction of $199,050.00. Following the sale, the director now directly owns 3,258 shares of the company’s stock, valued at $259,401.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Thomas M. Moriarty sold 20,547 shares of the business’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $81.17, for a total transaction of $1,667,799.99. Following the sale, the executive vice president now directly owns 43,178 shares in the company, valued at $3,504,758.26. The disclosure for this sale can be found here. Insiders sold 716,625 shares of company stock worth $58,318,431 over the last ninety days. Corporate insiders own 0.61% of the company’s stock.
Large investors have recently bought and sold shares of the business. Fieldpoint Private Securities LLC boosted its holdings in CVS Health Corporation by 333.3% in the second quarter. Fieldpoint Private Securities LLC now owns 1,300 shares of the pharmacy operator’s stock valued at $105,000 after purchasing an additional 1,000 shares during the last quarter. Arcadia Investment Management Corp MI boosted its holdings in CVS Health Corporation by 119.6% in the third quarter. Arcadia Investment Management Corp MI now owns 1,333 shares of the pharmacy operator’s stock valued at $108,000 after purchasing an additional 726 shares during the last quarter. MPS Loria Financial Planners LLC purchased a new stake in CVS Health Corporation in the second quarter valued at $119,000. Gemmer Asset Management LLC boosted its holdings in CVS Health Corporation by 15.3% in the second quarter. Gemmer Asset Management LLC now owns 1,509 shares of the pharmacy operator’s stock valued at $121,000 after purchasing an additional 200 shares during the last quarter. Finally, TB Alternative Assets Ltd. purchased a new stake in CVS Health Corporation in the second quarter valued at $121,000. 82.04% of the stock is currently owned by institutional investors.
CVS Health Corporation Company Profile
CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.
Receive News & Ratings for CVS Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corporation and related companies with MarketBeat.com's FREE daily email newsletter.